IGF2BP3 in gastric cancer: Unraveling an N6-methyladenosine-driven oncogenic axis for therapeutic targeting

doi:10.3748/wjg.116347

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 27

This Article

(7)

(8)

(0)

(2)

(63)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jul 21, 2026; 32(27): 116347
Published online Jul 21, 2026. doi: 10.3748/wjg.116347

Open in New Tab Full Size Figure Download Figure

Figure 1 IGF2BP3 promotes gastric cancer via N⁶-methyladenosine modification. N⁶-methyladenosine is dynamically regulated by writers, erasers, and readers. This modification participates in multiple aspects of RNA processing, including stability, translation, and decay. The IGF2BP3/FBXO32/cyclic guanosine monophosphate-protein kinase G axis represents a promising therapeutic target for gastric cancer. mRNA: Messenger RNA; m6A: N⁶-methyladenosine; GC: Gastric cancer; GTP: Guanosine triphosphate; cGMP: Cyclic guanosine monophosphate.

Citation: Feng QY, Yin SB, Luo LY, Dai LY, Luo XL. IGF2BP3 in gastric cancer: Unraveling an N⁶-methyladenosine-driven oncogenic axis for therapeutic targeting. World J Gastroenterol 2026; 32(27): 116347
URL: https://www.wjgnet.com/1007-9327/full/v32/i27/116347.htm
DOI: https://dx.doi.org/10.3748/wjg.116347

Feng QY, Yin SB, Luo LY, Dai LY, Luo XL. IGF2BP3 in gastric cancer: Unraveling an N⁶-methyladenosine-driven oncogenic axis for therapeutic targeting. World J Gastroenterol 2026; 32(27): 116347 [DOI: 10.3748/wjg.116347]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.